Physician profile
Junghee Che
NPI 1144510884
$20,263.75
in general payments reported to CMS, 2019-2025
47 companies · $6,189 in 2025
The $6,189 reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,137 · 2022: $2,824 · 2023: $4,354 · 2024: $5,759 · 2025: $6,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $20.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,281.54 |
| Education | $20.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,322.89 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,969.67 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Mayne Pharma Commercial LLC | $1,738.92 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,666.83 | 2021-2025 | |
| Lilly USA, LLC | $1,375.95 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $799.18 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $757.68 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $712.18 | 2022-2025 | Jardiance, Tradjenta, Glyxambi |
| Phathom Pharmaceuticals, INC. | $569.86 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $420.29 | 2024-2025 | Rexulti |
| Corcept Therapeutics | $388.88 | 2024-2025 | Korlym |
| Amgen INC. | $362.03 | 2021-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $305.65 | 2023-2025 | |
| Ibsa Pharma INC. | $290.88 | 2023-2025 | Tirosint, Licart, Flector |
| Teva Pharmaceuticals USA, INC. | $238.16 | 2021-2024 | Austedo Xr, Austedo |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $219.69 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $199.33 | 2024-2025 | Caplyta |
| Abbott Laboratories | $194.94 | 2023 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $193.16 | 2024 | Injectafer |
| Nestle Healthcare Nutrition INC. | $187.90 | 2022-2023 | |
| Lundbeck LLC | $163.86 | 2024-2025 | Rexulti |
| Aimmune Therapeutics, INC. | $104.08 | 2024-2025 | Zenpep |
| Medtronic, INC. | $87.97 | 2024-2025 | Intellis Adaptivestim |
| Allergan, INC. | $87.47 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $71.17 | 2023-2024 | Edarbyclor, Horizant, Horizant |
| Amarin Pharma, INC. | $70.82 | 2021 | |
| Exact Sciences Corporation | $57.33 | 2023-2024 | Cologuard Collection Kit |
| Insmed, INC. | $56.35 | 2025 | Arikayce, Brinsupri |
| Esperion Therapeutics, INC. | $50.41 | 2025 | Nexletol |
| Ardelyx, INC. | $49.45 | 2024 | Ibsrela |
| Xeris Pharmaceuticals, INC. | $48.44 | 2024 | Gvoke Hypopen |
| Genentech USA, INC. | $47.94 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $43.40 | 2021 | |
| Shield Therapeutics INC | $42.97 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $40.02 | 2023 | Spravato |
| Phadia US INC. | $37.44 | 2025 | Immunocap |
| E.R. Squibb & Sons, L.L.C. | $35.31 | 2025 | Cobenfy |
| Vbi Vaccine (Delaware) INC. | $34.55 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.82 | 2022 | |
| Edwards Lifesciences Corporation | $31.88 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $27.33 | 2025 | Watchman Access System |
| Alexion Pharmaceuticals, INC. | $27.14 | 2025 | Strensiq |
| Ascensia Diabetes Care US INC. | $22.60 | 2024 | |
| Mylan Specialty L.P. | $22.36 | 2024 | Yupelri |
| Viatris Specialty LLC | $22.03 | 2025 | Yupelri |
| Gilead Sciences, INC. | $19.11 | 2022 | |
| Echosens North America, INC. | $15.43 | 2024 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junghee Che listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.